|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:approval_authority
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:approves
|
gptkb:2017
treatment of certain types of cancer
|
|
gptkbp:bioequivalence
|
gptkb:Avastin
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:clinical_use
|
oncology
|
|
gptkbp:country_of_origin
|
gptkb:United_States
|
|
gptkbp:created_by
|
bevacizumab
|
|
gptkbp:developed_by
|
gptkb:Amgen
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:healthcare
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mvasi
|
|
gptkbp:indication
|
gptkb:disease
gptkb:Oncology
gptkb:cervical_cancer
ovarian cancer
|
|
gptkbp:infusion_time
|
30 to 90 minutes
|
|
gptkbp:ingredients
|
bevacizumab
|
|
gptkbp:invention
|
patented
|
|
gptkbp:manufacturer
|
gptkb:Amgen_Inc.
|
|
gptkbp:market_position
|
available
|
|
gptkbp:marketed_as
|
gptkb:Mvasi
|
|
gptkbp:mechanism_of_action
|
angiogenesis inhibition
|
|
gptkbp:patient_population
|
adults
pediatric patients
|
|
gptkbp:previous_name
|
bevacizumab-awwb
|
|
gptkbp:price
|
lower than branded alternatives
|
|
gptkbp:provides_guidance_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:recommissioned
|
required
|
|
gptkbp:related_to
|
gptkb:Avastin
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_measures
|
required
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
vomiting
diarrhea
rash
bleeding
hypersensitivity
thromboembolism
infusion reactions
neutropenia
gastrointestinal perforations
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor_(VEGF)
|
|
gptkbp:bfsParent
|
gptkb:Bevacizumab
|
|
gptkbp:bfsLayer
|
6
|